

The Potential Interaction of Ethionamide-Thyroid Hormone Receptor Induces Hypothyroidism

Ronny Lesmana^{1,2,*}, Firyali Rahmani Shidqi³, Hanna Goenawan^{1,2}, Iwan Setiawan^{1,2}, Marisca Evalina Gondokesumo⁴, Farida Suhud⁴, Nasrul Wathoni⁵

Ronny Lesmana^{1,2,*}, Firyali Rahmani Shidqi³, Hanna Goenawan^{1,2}, Iwan Setiawan^{1,2}, Marisca Evalina Gondokesumo⁴, Farida Suhud⁴, Nasrul Wathoni⁵

¹Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor 45363, INDONESIA.

²Physiology Molecular Laboratory, Biological Activity Division, Central Laboratory, Universitas Padjadjaran, Jatinangor 45363, INDONESIA.

³Undergraduate Program of Medical Doctor, Faculty of Medicine, Universitas Padjadjaran, Jatinangor 45363, INDONESIA.

⁴Faculty of Pharmacy, University of Surabaya, Surabaya 60294, INDONESIA.

⁵Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, INDONESIA.

Correspondence

Ronny Lesmana

Department of Biomedical Sciences, Faculty of Medicine; Physiology Molecular Laboratory, Biological Activity Division, Central Laboratory, Universitas Padjadjaran, Jatinangor 45363, INDONESIA.

E-mail: cloencool@gmail.com

History

- Submission Date: 15-04-2021;
- Review completed: 28-05-2021;
- Accepted Date: 03-06-2021.

DOI : 10.5530/pj.2021.13.

Article Available online

<http://www.phcogj.com/v13/i5>

Copyright

© 2021 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



ABSTRACT

Background: Hypothyroidism is a common side effect found in patients with multidrug-resistant tuberculosis taking ethionamide. The mechanism of ethionamide-induced hypothyroidism is potentially caused by the structure of ethionamide compounds chemically similar to thioamide, such as propylthiouracil (C₇H₈N₂S), which inhibits thyroid hormone synthesis. However, hypothyroidism is caused not only by a lack of production but also by signaling alteration. Thyroid hormone action is mediated by thyroid hormone receptors (TRs), members of the nuclear receptor superfamily that regulate their target genes. Unfortunately, there are limited studies on the potential interaction of ethionamide with TRs. **Objective:** In the present study, we want to elaborate on the potential interaction of ethionamide with TRs which might alter the thyroid hormone genomic regulation. **Methods:** Molecular docking studies were used to evaluate the potential interaction between ethionamide with TR α and TR β . **Results:** The molecular docking results on TR α showed more than one hydrogen bond-steric interaction formed from the ethionamide-amino acid residue interaction. Ethionamide-TR β interaction showed more than one steric interaction, but the hydrogen bonds are not visualized. The docking score between ethionamide and TR α is -7.373 kcal/mol and higher than its interaction with TR β . **Conclusion:** These findings indicate that ethionamide can interact with TR α and TR β . However, the ethionamide-TR α interaction is stronger than ethionamide-TR β interaction. Our study reports a novel mechanism of action of ethionamide-induced hypothyroidism.

Key words: Ethionamide, Hypothyroidism, Molecular docking, TR α , TR β .

INTRODUCTION

Ethionamide (2-ethyl pyridine-4-carbothioamide, C₈H₁₀N₂S, ETH) is a nicotinamide derivative that has a molecular structure of ETH. ETH belongs to the anti-tuberculosis agent class that is used as a second-line treatment regimen in patients with multidrug-resistant tuberculosis (MDR-TB).¹ ETH has several adverse effects.²⁻⁴ The most common adverse effect and concern is that ETH can cause mild to moderate hypothyroidism.⁵⁻¹¹ On the basis of studies conducted in several countries, there are data on patients with hypothyroidism due to ETH in Egypt (39.5%), Botswana (16.2%), Russia (17.2%), Peru (10%), and Lesotho (69%).⁵⁻⁸ Hypothyroidism due to ETH is common in children and people with human immunodeficiency virus (HIV).⁹⁻¹¹

Thyroid hormones (THs) (3,5,3'-triiodo-L-thyronine or T₃; 3,5,3',5'-tetraiodo-L-thyronine or thyroxine or T₄) signaling plays critical roles in regulating mammalian development and metabolism, including the development of the central nervous system in infants, skeletal growth in children, and the normal function of multiple organ systems in adults.^{12,13} TH regulation is under negative feedback regulation by the hypothalamic-pituitary-thyroid axis. Thyroid-stimulating hormone (TSH) from the anterior pituitary binds to the TSH receptor (TSHR) located on the basolateral membrane of thyroid follicular epithelial cells and then promotes the production of the THs, T₃ and T₄.¹² TSHR is a glycoprotein hormone receptor, a subfamily of class A G-protein-coupled receptors (GPCRs). GPCRs are essential for signal transducers and regulators.¹⁴ Direct

TSHR activation and G proteins' coupling leads to a cascade of complex intracellular events resulting in thyrocyte growth and hormone production.¹⁵ TSH is a marker for thyroid function, and a normal TSH level indicates the proper thyroid function. On the basis of the definition of hypothyroidism used by Satti et al., hypothyroidism is defined using the cutoff TSH level of >10 mIU/mL.⁶

TH's action is mediated by TH receptors (TRs) that are members of the nuclear receptor superfamily that act as ligand-dependent transcription factors, which bind to a specific DNA sequence called the TH response element (TRE) as a homodimer or as a TR-heterodimer with the retinoid X receptor (RXR). Two different genes express two different TR subtypes, TR α and TR β .¹⁶ TR α regulates heart rate and contractility, and TR β controls cholesterol metabolism and TSH production.¹⁷ In the absence of ligand (T₃), TR is associated with co-repressor proteins, and then gene transcription is inhibited. However, in the presence of T₃, the co-repressors are replaced by coactivator complexes, including the steroid receptor coactivators (SRC)-1, SRC-2, and SRC-3 to activate transcription. TH exerts its actions through genomic and nongenomic pathways.^{18,19} If hypothyroidism occurs, it interferes with cell metabolism by disrupting the signaling and regulation of the expression of various genes in the nucleus, cytoplasm, and mitochondria, resulting in mitochondrial dysfunction and decreased cell viability. Hypothyroidism could affect all tissues and organs. It can cause muscle, skin, pulmonary, cardiac, gastrointestinal, renal, and neurological dysfunctions.¹²

Cite this article: Lesmana R, Shidqi ER, Goenawan H, Setiawan I, Gondokesumo ME, Suhud F, et al. The Potential Interaction of Ethionamide-Thyroid Hormone Receptor Induces Hypothyroidism. *Pharmacogn J.* 2021;13(5):.

Currently, the known mechanism of ETH-induced hypothyroidism occurs because ETH compounds chemically similar to thioamide, such as propylthiouracil.²⁰ These drugs can cause hypothyroidism by inhibiting TH synthesis through a mechanism of iodine organification inhibition.^{20–22} However, it is unknown whether the genomic pathway also contributes to ETH-induced hypothyroidism. Molecular docking is a computational procedure that attempts to efficiently predict the noncovalent binding between a receptor (protein) and a ligand.²³ Molecular docking algorithms execute quantitative predictions of binding energetics, providing rankings of docked compounds based on ligand–receptor complex binding affinity.²⁴ Thus, molecular docking will show potential ETH–TR α and ETH–TR β interactions. Our data will reveal another possible mechanism of ETH-induced hypothyroidism.

MATERIALS AND METHODS

All the *in silico* calculations were performed using a Lenovo IdeaPad 3 15-inch with an Intel® Core™ i5-1035G1 processor and a memory of 8 GB DDR4 2667 MHz (4 GB Soldered + 4 GB DIMM) and running on a Windows 10 Home 64 operating system.

Ligand preparation

The molecular structure of ETH (PubChem CID 2761171) was downloaded from PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) in the structure data file format. The ETH structure was then opened with Chem3D software to minimize energy and saved in protein data bank (PDB) format. Then, the three-dimensional (3D) ETH structure was optimized using AutoDockTools 1.5.7 software (<http://autodock.scripps.edu/resources/adt>). Optimization is done by adding hydrogen atoms, removing water molecules, and partial charging of Gasteiger charges. We then searched for geometric conformation based on the torsion of ETH and got the geometric conformation with the lowest energy. The input file was generated in the PDBQT format.

Receptor preparation

The crystal structures of the TR α (PDB ID: 4LN α) and TR β (PDB ID: 3JZC, 1Q4X) were downloaded from the PDB (<http://www.rcsb.org/pdb/home/home.do>) in PDB format. The 3D structure files of the TR α and TR β crystal structures were opened and modified with Discovery Studio Visualizer software, version 4.0 (BIOVIA/Accelrys Inc., San Diego, CA, USA). The water molecules and other substructures (bound or ligand molecules) were removed from the coordinate file before docking. The water molecules were deleted to simplify the energy calculation for the simulation. The results (without ligands) were saved in PDB format. The ETH structure's PDB format was opened with AutoDockTools 1.5.7 software and was followed by adding Kollman charges and polar hydrogens. Then, the input file was generated in the PDBQT format.

Parameter grid and docking simulation

Molecular docking was performed to identify and calculate the receptor–ligand interactions. The unliganded TR α and TR β were used for individual docking with ETH. AutoGrid was used for the preparation of the grid map using a grid box with a docking box. The coordinates for docking were determined through a grid box 60 × 60 × 60 Å for TR α and 60 × 60 × 60 Å for TR β . The box spacing was 0.375 Å. Finally, AutoDock was run using a maximum number of 10,000 retries and 27,000 generations. The docking possibilities were calculated using a genetic algorithm with local search. For each ETH, the stimulation was composed of 1000 docking runs using the standard AutoDock parameters. Molecular docking was done using AutoDock 4 and AutoDock Vina as docking software (Trott and Olson, 2010) using a blind docking strategy to include the entire possible binding site for the ligands. The binding affinity was expressed as the binding free energy (kcal/mol).

Data analysis from molecular docking

The value of free binding energy can be evaluated by opening the docking “dock.dlg” file using Notepad++ (downloaded from <https://notepad-plus-plus.org/download/v7.5.8.html>). We then observed the histogram for each cluster to find the lowest bond energy affinity for each docking result—the lower the energy, the stronger the interaction. The conformation of molecular docking results was visualized using AutoDockTools. Visualization of the bonds that occur between the ligands of each macromolecule is done using the PyMOL Visualization Tool (downloaded from <https://pymol.org/2/>) and Molegro 5.5 software. The best post-docking compound structure must fulfill the following requirements: it has the lowest energy, and the molecules are in the same active site as the native ligand, which can be visually observed in the protein structure. Observations of ligand–protein interactions, including hydrogen bonding, steric (van der Waals) interactions, and electrostatic interactions, were performed for the pose with the highest score.

RESULTS AND DISCUSSION

Method validation

Molecular docking is performed to study the binding environment for the ETH interacting within the receptors TR α and TR β . The molecular docking results reveal the complex ligand–receptor interactions and active conformations. The validation of docking was conducted by redocking the native ligand of the receptor into its active site. Native ligands are built-in ligands that bind to the target protein in the PDB file when downloaded. The crystal structures used in our docking studies are summarized in Table 1. Three molecules (GC-24, TRIAC, and T4) with known dissociation constants (K_i values) for TR α and TR β were docked to the receptor proteins. After redocking, the native ligand structure conformation resulted from the redocking overlap with the native ligand structure conformation in PDB. Validation evaluation parameters are root mean square deviation (RMSD) and visual position. RMSD is the difference between the predicted value and the observed experimental value and is a measure of the precision value with consistent results for repeated experiments. The RMSD evaluation was conducted by determining the RMSD value of the ligands based on the following ranges: RMSD ≤ 1.0 Å for good or true conformations, 1.0 Å < RMSD ≤ 2.0 Å for near true conformations, 2.0 Å < RMSD ≤ 3.0 Å for conformations with error, and RMSD > 3.0 Å for poor conformation (Bajda et al., 2014). Criteria of acceptance were set with the value of RMSD below 2.0 Å. The RMSD calculation results show that the RMSD of TR α (PDB ID: 4LN α) is 1.918 Å, TR β (PDB ID: 3JZC) is 0.814 Å, and TR β (PDB ID: 1Q4X) is 0.755 Å. All crystal structures used in our docking studies have RMSD below 2.0 Å. We proved that our docking method is appropriate to investigate the ETH–receptor protein interaction with this validation.

Docking to the TRs

In this study, we evaluated ETH–TR α and ETH–TR β interactions. Previous studies suggested that ETH may contribute to thyroid dysfunction because ETH compounds are chemically similar in structure to thioamides, such as propylthiouracil and methimazole (C₄H₆N₂S).²⁰ ETH acts as a competitive inhibitor of thyroid peroxide, which causes inhibition of iodine uptake into thyroid cells, thereby

Table 1: Crystal structures used in our docking studies and their RMSD.

TR isoform	Ligand	PDB-ID	RMSD (Å)
α	T4	4LN α (Souza et al. 2014)	1.918
β	GC-24	1Q4X (Borngraeber et al. 2003)	0.755
	TRAC	3JZC (Martinez et al. 2009)	0.814

inhibiting the formation of iodine. The inhibition of TH synthesis decreases T_3 and T_4 in the circulation.²⁰⁻²² However, hypothyroidism is caused not only by lack of TH production but also by signaling alteration. However, the molecular mechanisms of how ETH causes hypothyroidism remain unknown, and the literature regarding the specific effects of ETH on TR is lacking.

After validating the binding pocket by redocking the original ligand to the receptor to its active site, the ETH compound is bound to the TR α and TR β binding pockets. To investigate ETH's binding modes to the TR-ligand-binding domain (LBD), we generated *in silico* binding models by molecular docking using AutoDocks Vina (Trott and Olson, 2010). The 3D docking configuration in the form of ETH-receptor interactions are shown in Figure 1.

The molecular docking results on TR α showed that two hydrogen bonds formed from the ETH compound molecule interaction with the amino acid residues Arg 228 and Met 259 in the 4LN α receptor active site (Figure 2A). Hydroxy groups form hydrogen bonds at the center of the structure, amide groups (peptide bonds), or other groups that can be hydrogen bond donors or acceptors. In the hydrogen bonds formed with the Arg 228 and Met 259 residues, ETH received proton from the two residues. The ETH-TR α protein interaction is also through steric interactions with the amino acid residues of Arg 266 (Figure 2A). Steric effects are nonbonding interactions that influence the shape (conformation) and reactivity of ions and molecules. The interaction through hydrogen bonds and steric interactions at the active site cause the docking score (rerank score) between ETH and TR α to have the highest value, which is $-7,373$ kcal/mol (Table 2).




Figure 1: Ethionamide can bind to the active site of TR α and TR β . Three-dimensional (3D) docking conformation in the form of interactions between ethionamide (green) and receptors (A) 4LN α , (B) 1Q4X, and (C) 3JZC.




Figure 2: The interaction between ethionamide with TR α and TR β . Two-dimensional (2D) structure of hydrogen bonding interactions (blue dashed line) and steric interactions (red dashed line) between ethionamide compound molecules and amino acids in the active site TRs. (A) In TR α (4LN α), ethionamide forms two hydrogen bonds with the amino acids Arg 228, Met 259, and shows one steric interaction with Arg 266. (B) in TR β (1Q4X) shows two steric bonds with Ala 317, Ala 279. Whereas (C) shows two steric bonds between TR β (3JZC) and ethionamide in amino acids Ala 234, Asn 331. Images obtained from the Molegro 5.5 program.

Table 2: Molecular docking result.

Compound	TR Isoform	Protein (PDB ID)	ΔG (kcal/mol)	Hydrogen Bond Interaction	Steric Interaction
Ethionamide	α	4LN α	-7.373	Arg 228, Met 259	Arg 266
	β	1Q4X	-7.283	-	Ala 317, Ala 279
		3JZC	-7.243	-	Asn 331, Ala 234

The molecular docking of TR β showed that there is a steric interaction between the ETH compound molecule and the 1Q4X receptor on the amino acid residues Ala 317 and Ala 279 (Figure 2B). Meanwhile, the steric interaction between ETH compound molecules and the 3JZC receptor is found in the amino acid residues Asn 331 and Ala 234 (Figure 2C). Hydrogen bonds were not found. The ETH's affinity

bonds with the two TR β receptors, 1Q4X and 3JZC, were $-7,283$ and $-7,243$ kcal/mol, respectively.

Using *in silico* analysis, we found that ETH may directly interact with the TR-LBD. Like other nuclear receptors, the TR-LBDs have a core binding site for T₃, where the ligand is buried. The binding of THs can change the conformation of TRs (Souza et al., 2014; Moras et al., 2015). We showed a potential mechanism of action of ETH-induced hypothyroidism by direct binding of ETH to TRs (Figure 1). Our data showed that the docking score between ETH and TR α has a higher value than its interaction with TR β . The higher the docking score, the lower the ligand-protein interaction energy and the higher the biological activity.

The TH nuclear receptor consists of several domain structures. The differences in the domain structure characteristics lead to the formation of several TR α and TR β isoforms. TR α and TR β isoforms have different locations and functions. TR α_1 has the highest expression in the bone, gastrointestinal tract, cardiac and skeletal muscle, and central nervous system. TR α_2 and TR α_3 are predominant in the brain, kidney, testis, brown adipose tissue, and skeletal muscle. Although a dominant-negative function has been attributed to mammalian TR α_2 , which is widely co-expressed with TR α_1 , TR α_2 modulates thyrotropin-releasing hormone gene expression in the hypothalamus.²⁵ Thus, ETH-TR α interaction may affect these organs' activity and metabolic function. However, ETH-TR β interaction may affect the organs' activity and metabolic function that have these receptors. TR β_1 is most abundant in the liver, kidney, and inner ear. TR β_2 is predominant in the hypothalamus, pituitary, cochlea, and retina, and TR β_4 is a relatively high expression in the brain and kidney.²⁶⁻²⁸

ETH binding to TR-LBD may also induce conformational changes in the structure of TRs and then regulate their target genes in specific cell targets. A multifaceted cascade of events results in the binding of TRs to TREs and culminates in the modulation of target gene expression in response to TH.²⁹ Previous studies conducted by Lesmana et al. showed that ETH could significantly up-regulate the expression of thyroid receptor and iodothyronine deiodinase in the soleus and cardiac muscle cells.³⁰ Deiodinase is essential for the biological activity of TH. The up-regulation of TR and iodothyronine deiodinase gene expression may indicate a compensation for hypothyroidism in the muscle environment. The hormone receptor can activate or repress gene transcription depending on the promoter context and ligand-binding status.¹⁹ In the absence of T₃, the unliganded TR undergoes conformational changes and recruits co-repressor complexes that include the nuclear co-repressor, the silencing mediator for RXR and TR, and histone deacetylases.^{29,31} This co-repressor complex integrates several enzymatic activities that modify chromatin towards a closed structure, resulting in a transcriptionally silent state.¹⁸ However, the presence of T₃ that binds to TR resulted in a new set of activator proteins that bind to the receptor. These activator proteins include the SRC-1, nuclear coactivator 1, the transcriptional intermediary factor 2, the cAMP-response element-binding protein-binding protein (CBP), also known as p300, the p300/CBP-associated factor, and histone acetyltransferase. Activator protein activity leads to changes in chromatin structure and the subsequent transcription of the target gene.^{29,31}

Molecular docking results showed a potential ETH-thyroid receptor interaction. These findings indicate that ETH may alter TH signaling through TR signaling pathways that may contribute to causing hypothyroidism in patients with MDR-TB. However, further studies and research are needed to test the interaction and determine the next steps in improving the outcome of MDR-TB treatment.

CONCLUSIONS

On the basis of the results of molecular docking, ETH can interact with TR α and TR β . However, based on the value of free energy binding and hydrogen bonds, ETH-TR α interaction is better than ETH-TR β interaction. We proposed a novel mechanism of action of ETH-induced hypothyroidism by direct binding of the ETH to TRs.

ACKNOWLEDGEMENT


The authors would like to thank Ardo Sanjaya for proofreading the article. This article was funded by PDUPT research grant from Indonesia Ministry of Research to Ronny Lesmana (2020).

REFERENCES

1. PubChem [database on the Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2761171, Ethionamide; [cited 2020 June 25].
2. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Ethionamide>
3. World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, Switzerland. 2019.
4. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology. New York: McGraw-Hill; 2012. p. 843-844.
5. Ramachandran G, Swaminathan S. Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications. Drug Safety. 2015;38(3), 253-269.
6. Tola HH, Holakouie-Naieni K, Lejisa T, et al. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. PLoS One. 2019;14(6):e0218487.
7. Satti H, Mafukidze A, Jooste PL, McLaughlin MM, Farmer PE, Seung KJ. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis. 2012;16(4):468-72.
8. Munivenkatappa S, Anil S, Naik B, Volkman T, Sagili KD, Akshatha JS, Buggi S, Sharada MA, Kulkarni S, Chadha VK, Moonan PK. Drug-induced hypothyroidism during anti-tuberculosis treatment of multidrug-resistant tuberculosis: notes from the field. Journal of tuberculosis research. 2016;4(3):105
9. Modongo C, Zetola NM. Prevalence of hypothyroidism among MDR-TB patients in Botswana. Int J Tuberc Lung Dis. 2012;16(11):1561.
10. Brust JC, Shah NS, Van Der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse events in an integrated, home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. Journal of acquired immune deficiency syndromes (1999). 2013;62(4):436.
11. Andries A, Isaakidis P, Das M, et al. High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. PLoS One. 2013;8(10):e78313.
12. Thee S, Zöllner EW, Willemse M, Hesselting AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis. 2011;15(9):1191-i.
13. Molina PE, Ashman R. Endocrine Physiology. New York: McGraw-Hill; 2013. p.88-90.
14. Stathatos N. Thyroid Physiology. Med Clin North Am. 2012;96(2):165-173.
15. Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25(1):4-12.
16. Davies TF, Latif R. Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies. Expert Opin Ther Targets. 2015;19(6):835-847.

17. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. *Physiol Rev.* 2014;94(2):355-382.
18. Korta P, Pocheć E. Glycosylation of thyroid-stimulating hormone receptor. *Endokrynol Pol.* 2019;70(1):86-100.
19. Weitzel JM, Iwen KA. Coordination of mitochondrial biogenesis by thyroid hormone. *Mol Cell Endocrinol.* 2011;342(1-2), 1–7.
20. Cioffi F, Senese R, Lanni A, Goglia F. Thyroid hormones and mitochondria: With a brief look at derivatives and analogues. *Mol Cell Endocrinol.* 2013;379(1-2), 51–61.
21. Choi J, Park SJ, Jee JG. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. *European Journal of Medicinal Chemistry.* 2015;106,157–166.
22. Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. *Acc Chem Res.* 2013;46(11):2706-2715.
23. Tousson E, Ibrahim W, Arafa N, Akela MA. Monoamine concentrations changes in the PTU-induced hypothyroid rat brain and the ameliorating role of folic acid. *Human & experimental toxicology.* 2012;31(3):282-9.
24. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 2010;31(2):455-461.
25. de Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular docking as a popular tool in drug design, an insilico travel. *Adv Appl Bioinform Chem.* 2016;9:1-11.
26. Guissouma H, Ghaddab-Zroud R, Seugnet I, Decherf S, Demeneix B, Clerget-Froidevaux MS. TR $\alpha 2$ exerts dominant negative effects on hypothalamic Trh transcription in vivo. *PLoS One.* 2014;9:e95064.
27. Flamant F, Gauthier K. Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. *Biochim Biophys Acta.* 2013;1830:3900–3907
28. Hahm JB, Privalsky ML. Research resource: identification of novel coregulators specific for thyroid hormone receptor- $\beta 2$. *Mol Endocrinol.* 2013;27:840–859.
29. Vella KR, Hollenberg AN. The actions of thyroid hormone signaling in the nucleus. *Mol Cell Endocrinol.* 2017;458:127–135
30. Anyetei-Anum CS, Roggero VR, Allison LA. Thyroid hormone receptor localization in target tissues. *J Endocrinol.* 2018;237(1):R19-R34.
31. Lesmana R, Setiawan S, Efza F, Pratiwi YS, Iqbal GM, Goenawan H, Sylviana N, Supratman U. Ethionamide Alters Thyroid Receptor Gene Expression in Rats' Muscle. *The Indonesian Biomedical Journal.* 2020;12(3):220-6.
32. Giammanco M, Di Liegro CM, Schiera G, Di Liegro I. Genomic and Non-Genomic Mechanisms of Action of Thyroid Hormones and Their Catabolite 3,5-Diiodo-L-Thyronine in Mammals. *Int J Mol Sci.* 2020;21(11):4140.

GRAPHICAL ABSTRACT



ABOUT AUTHORS



Ronny Lesmana, had graduated as medical doctor and also finished his master level from Faculty of Medicine at Universitas Padjadjaran, further he continued his Doctorate level at Gunma University. Since 2006 until now, he has been working as a lecturer and associate professor at the Faculty of Medicine, University of Padjadjaran. His interest is exercise physiology and endocrinology. Latest publication is about Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageing, in which we had explored the modulation of YAP/TAZ or the Hippo pathway in general may offer potential new strategies for the prevention or treatment of ageing.




Firyali Rahmani Shidqi is a fourth-year medical student at the Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. She received a bachelor's degree in the Medical Program, Faculty of Medicine, Universitas Padjadjaran. Currently, Her interest is study and research related with internal medicine as well as physiology and biomedical sciences.



Hanna Goenawan, was graduated from Faculty of Medicine, Universitas Padjadjaran and continue to pursue PhD degree at Dept of Neurophysiology, Gunma University Graduate School of Medicine. Currently, she has been working as assistant professor in Physiology Division, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran. Her research theme is focused on molecular physiology and exercise physiology on body organ system.



Iwan Setiawan, had graduated as medical doctor from Faculty of Medicine at Universitas Padjadjaran, further he continued his Doctorate level at Tubingen University. Currently, he has been working as associate professor at the Faculty of Medicine, University of Padjadjaran. His interest is exercise physiology and endocrinology. Latest publication is about Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageing, in which we had explored the modulation of YAP/TAZ or the Hippo pathway in general may offer potential new strategies for the prevention or treatment of ageing.



Farida Suhud, had graduated from the Faculty of Pharmacy, Airlangga University, further study S2 and S3 at the same place. Since 1989 until now, he has worked as a lecturer at the Faculty of Pharmacy, University of Surabaya. His field of study so far is Medicinal Chemistry. The design of urea derivative drugs that work as anticancer is the first choice taken to complete the doctoral dissertation. The drug design is aimed at the discovery of new anticancer drugs that work selectively, effectively and safely. It is hoped that the research conducted can make a valuable contribution to society in the future, considering that cancer cases are increasing from year to year.



Marisca Evalina Gondokesumo had finished studied at Biomedical Sciences Doctoral Program Faculty of Medicine, Brawijaya University, Malang city, East Java, Indonesia. She is working as a lecturer in Faculty of Pharmacy, University of Surabaya (UBAYA) East Java, Indonesia. Her latest publication was "Microstructural characterization of the Garcinia mangostana fruit at Different Maturity Level". Her latest research was about Antioxidant Activity Analysis of Six Different Maturity Levels of Mangosteen Rind Extract (*Garcinia mangostana* Linn.) using Electron spin resonance (ESR).



Dr. Nasrul Wathoni obtained his Doctoral degree in Pharmaceutical Sciences from Kumamoto University, Japan. Currently he is working as Associate Professor at Department of Physical Pharmaceutic, Faculty of Pharmacy Universitas Padjadjaran, Bandung, Indonesia. His main area of interest related to Dermal and Transdermal Drug Delivery System. His area of expertise includes hydrogel film and polymeric nanoparticle based natural polysaccharides.

Cite this article: Lesmana R, Shidqi ER, Goenawan H, Setiawan I, Gondokesumo ME, Suhud F, et al. The Potential Interaction of Ethionamide-Thyroid Hormone Receptor Induces Hypothyroidism. *Pharmacogn J.* 2021;13(5):.

Pharmacognosy Journal

An Open Access, Peer Reviewed Journal in the field of
Pharmacognosy

[Articles In Press](#)[Current Issue](#)[Archives](#)[RSS Feeds](#)[Submit Article](#)

Editorial Board | Pharmacognosy Journal

Editors & Editorial Board Members (2021)

Dr. Djemli Samir

Department of Biology , Applied Neuroendocrinology Laboratory
Badji Mokhtar Annaba University
Algeria

Dr. Raghava Naidu, Ph.D

Department of Human Oncology,
University of Wisconsin,
1111, Highland Ave, Madison,
Wisconsin 53705, USA

Dr. Karim Raafat

Associate Professor of Pharmacognosy and Phytochemistry,
Pharmaceutical Sciences Department,
Faculty of Pharmacy,
Beirut Arab University (BAU),
Beirut 115020, Lebanon

Ourlad Alzeus Tantengco, MD-PhD Molecular Medicine

College of Medicine, University of the Philippines Manila
Pedro Gil Street, Ermita, Manila, Philippines, 1000

Janib Achmad

Lecturer of Faculty of Fisheries and Marine Science,
University of Khairun Ternate
Kampus 2 Jalan Pertamina, Kelurahan Gambesi,
Ternate Selatan

Muammar Fawwaz, Ph.D

Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Universitas Muslim Indonesia
Makassar 90231, South Sulawesi, Indonesia

Hany Ezzat Khalil

Associate Professor,
College of Clinical Pharmacy,
King Faisal University,

KSA

Emad Yousif

Department of Chemistry

College of Science

Al-Nahrain University

Baghdad, Iraq

Sughosh Upasani

R.C Patel Institute of pharmacy,

Shirpur, Dist-Dhule, Maharashtra,

India.

Gurusiddaiah suresh kumar

Scientist

Dept of biochemistry

CSIR-CFTRI

Mysore, Karnataka, INDIA

Arjun Patra

Assistant Professor

School of Pharmaceutical Sciences

Guru Ghasidas Central University

Koni, Bilaspur - 495 009

Chattisgarh, India

Francis O. Atanu, Ph.D

Department of Biochemistry

Faculty of Natural Sciences

Kogi State University

Anyigba, Nigeria.

Vijay Kumar Chattu

Faculty of Medical Sciences

University of the West Indies

St. Augustine, Trinidad & Tobago.

Dr.Kunle Okaiyeto, PhD

Applied and Environmental Microbiology Research Group (AEMREG)

Department of Biochemistry and Microbiology

University of Fort Hare

Alice campus

5700, Alice

South Africa.

Dr. Srisailam Keshetti, Ph.D

Principal, University College of Pharmaceutical Sciences, Satavahana University
Karimnagar 505001

Telangana

INDIA

Dr. Gayathri M Rao

Associate Professor

Department of Biochemistry

Kasturba Medical College, Mangaluru.

Shuge Tian

Experimental Teaching Demonstration Center of TCM in Xinjiang Medical University

Department of traditional medicine, TCM

Xinjiang Medical University

Xinjiang CHINA 830054

Dr. Ramachandra Setty Siddamsetty,

Professor, Govt College of Pharmacy,

Mission Road, Bengaluru, INDIA

Dr. (Mrs.) Sayyada Khatoon

HOD, Pharmacognosy Division

CSIR-National Botanical Research Institute,

Rana Pratap Marg, Post Box 436,

Lucknow-226001 (U.P.) India

Dr. A. Sajeli Begum

Department of Pharmacy

Birla Institute of Technology & Science

Hyderabad, India

Olga Silva

Department of Pharmacological Sciences,

Faculdade de Farmácia,

Universidade de Lisboa, Portugal

Xinwen Wang

Department of Clinical Pharmacy

University of Michigan

USA

Roman Lysiuk

Department of Pharmacognosy and Botany,

Danylo Halytsky Lviv National Medical University,

Pekarska,69., Lviv 79010, Ukraine

Arif Nur Muhammad Ansori

Universitas Airlangga

Indonesia

Prabhu Manickam Natarajan

Specialist in Periodontics, College of Dentistry

Ajman University of Science and Technology, UAE

Neeta Mahesh Deshpande

Rural Institute of Ayurved Research Centre And Hospital

Mayani, Satara, Maharashtra, India

Enter terms then hit Search...



[Articles In Press \(/inpress\)](#) [Current Issue \(/v15/i6\)](#) [Archives \(/archives\)](#) [RSS Feeds \(/rss.xml\)](#)

[Submit Article \(https://www.phcogj.info\)](https://www.phcogj.info)

HOME (/) / PHARMACOGNOSY JOURNAL,
VOL 13, ISSUE 5, SEP-OCT, 2021

Pharmacognosy Journal, Vol 13, Issue 5, Sep-Oct, 2021

RECENT ARTICLES



[\(/article/1633\)](/article/1633)

Original Article

MIC and MKC Analysis of Herbal Medicine in Indonesia Against *Mycobacterium tuberculosis* (</article/1633>)

Sesilia Rante Pakadang, Maria Hilaria, Sisilia Teresia Ro Dewi, Santi Sinala,

Pharmacognosy Journal, 13(5):1058-1064

DOI: 10.5530/pj.2021.13.137

Published: Thu, 2-Sep-2021

[Read More \(/article/1633\)](/article/1633)

Original Article

Chitosan-Tripolyphosphate Nanoparticles of Mango Ginger (*Curcuma mangga*) Extract: Phytochemical Screening, Formulation, Characterization, and Antioxidant Activity (</article/1634>)


Bayyinatul Muchtaromah, Didik Wahyudi, Mujahidin Ahmad, Arif Nur Muhammm Ansori, Rahmi Annisa, Lil Hanifah

Pharmacognosy Journal, 13(5):1065-1071

DOI: 10.5530/pj.2021.13.138

Published: Thu, 2-Sep-2021

[Read More \(/article/1634\)](/article/1634)



[\(/article/1634\)](/article/1634)

Original Article

Total Phenol Content and Gastric Anti-Ulcer Activity of Hydroalcoholic Extract of *Persea caerulea* (Ruiz & Pav.) Mez. Bark (</article/1635>)

Abhel A. Calderón-Peña, Cinthya L. Aspajo-Villalaz, Carmen R. Silva-Correa, Víctor E. Villarr La Torre, María V. González-Bias, Orlando E. Pretel-Sevillano, Marco L. Salazar-Castillo, Maricielo Vaella-Alarcón, Franco Huaccha-Cáceres, Jonatam León-Soto, Whendy Alaya-Davirán, Anabel D. González-Siccha, William Antonio Sagástegui-Guarníz, Luz M. Guerrero-Espino, Julio Hilario-Vargas



[\(/article/1635\)](/article/1635)

Pharmacognosy Journal, 13(5):1072-1078



DOI: 10.5530/pj.2021.13.139

Published: Thu, 2-Sep-2021

[Read More \(/article/1635\)](#)

Original Article

Anti-diabetic Activity of the Red Dragon Fruit Peel (*Hylocereus polyrhizus*) in Ethanol Extract against Diabetic Rats (/article/1636)


Ruqiah Ganda Putr Panjaitan,

Pharmacognosy Journal,13(5):1079-1085

DOI: 10.5530/pj.2021.13.140

Published: Fri, 3-Sep-2021

[Read More \(/article/1636\)](#)



[\(/article/1636\)](#)

Original Article

Antibacterial Activities of Cationic Porphyrins and Porphyrin Encapsulated Gold Nanorods on Bacterial Cell Lines (/article/1637)


Hlapisi N, Maliehe TS, Oluwafemi OS, Songca SP, Langaniso L, Motaung TE

Pharmacognosy Journal,13(5):1086-1096

DOI: 10.5530/pj.2021.13.141

Published: Thu, 2-Sep-2021

[Read More \(/article/1637\)](#)



[\(/article/1637\)](#)

Original Article

Ethnobotanical Study of the Traditional Use and maintenance of Medicinal Plants by the People of Aleta-Chuko Woreda, South Ethiopia (/article/1638)


Tizazu Gebre, Bhaskarrao Chinthapalli

Pharmacognosy Journal,13(5):1097-1108

DOI: 10.5530/pj.2021.13.142

Published: Thu, 2-Sep-2021

[Read More \(/article/1638\)](#)



[\(/article/1638\)](#)

Original Article

Single Factor Effect of Natural Deep Eutectic Solvent Citric Acid-Glucose Based Microwave-Assisted Extraction on Total Polyphenols Content from *Mitragyna speciosa* Korth. Haval Leaves (/article/1639)


,Arsyik Ibrahim, Bakti Puji Rahayu, M Arifuddin, Yuspian Nur, Wisnu Cahyo Prabowo, ,Neneng Siti Silfi Ambarwati, Laode Rijai, Islamudin Ahmad

Pharmacognosy Journal,13(5):1109-1115

DOI: 10.5530/pj.2021.13.143

Published: Thu, 2-Sep-2021

[Read More \(/article/1639\)](#)



[\(/article/1639\)](#)


Original Article

Myocardium Neutrophil Infiltration in Rat Model with Acute Myocardial Infarction Treated by Ramipril (/article/1640)

Biomechy Oktomalioputri, Meutia Savitri, Dwisari Dillasamola,

Pharmacognosy Journal,13(5):1116-1121

DOI: 10.5530/pj.2021.13.144



[\(/article/1640\)](#)

Published: Thu, 2-Sep-2021

[Read More \(/article/1640\)](#)

Original Article

Phytochemical and Biological Characterization of Aqueous and Ethanolic Extracts of *Parthenium hysterophorus* (/article/1641)


MA Alfaro Jiménez,Zugasti Cruz,SY Silva Belmares,JA Ascacio Valdés,CA Sierra Rivera

Pharmacognosy Journal,13(5):1122-1133

DOI: 10.5530/pj.2021.13.145

Published: Thu, 2-Sep-2021

[Read More \(/article/1641\)](#)



[\(/article/1641\)](#)

Original Article

Single-Dose and Combined-Dose of Nanoparticles from Soursop Leaves (*Annona muricata* L.) and Sappan Wood (*Caesalpinia sappan* L.) Induced Apoptosis and Necrosis in HeLA Cells (/article/1642)


Okid Parama Astirin,Adi Prayitno,Anif Nur Artanti,Elisa Herawati,Afiyati Nur 'Ain Saad,Ajeng Dara Firstlia

Pharmacognosy Journal,13(5):1134-1142

DOI: 10.5530/pj.2021.13.146

Published: Thu, 2-Sep-2021

[Read More \(/article/1642\)](#)



[\(/article/1642\)](#)

Original Article

In Silico Analysis of Pinostrobin Derivatives from *Boesenbergia pandurata* on ErbB4 Kinase Target and QSPR Linear Models to Predict Drug Clearance for Searching Anti-Breast Cancer Drug Candidates (/article/1643)


Ersanda Nurma Praditapuspa, ,Tri Widiandani

Pharmacognosy Journal,13(5):1143-1149

DOI: 10.5530/pj.2021.13.147

Published: Thu, 2-Sep-2021

[Read More \(/article/1643\)](#)



[\(/article/1643\)](#)

Research Article

Xanthine Oxidase Inhibition Activity and ADMET Properties of Terap (*Artocarpus odoratissimus* Blanco) Leaves Metabolites: Phytochemical Screening and in silico Studies (/article/1644)


Nisa Naspiah,Mohammad Rizki Fadh Pratama,

Pharmacognosy Journal,13(5):1150-1160

DOI: 10.5530/pj.2021.13.148

Published: Thu, 14-Oct-2021

[Read More \(/article/1644\)](#)




[\(/article/1644\)](#)

Research Article

Evaluation of the Anticonvulsant, Anxiolytic, Sedative, and Neuroprotective Activities of Polysaccharides from Mycelium of Two *Ganoderma* Species (/article/1646)

Veronica Nunez-Urquiza,Juana Villeda-Hernandez,Elizur Montiel-Arcos,Isaac Tello,Victoria Campos-Pena,Maribel Herrera-Ruiz,María del Carmen Gutiérrez,Vera Petricevich,María Angélica Santana,Martha Navarro,Angélica Berenice Aguilar-Guadarrama,Gabriel Navarrete-Vázquez,Irene



[\(/article/1646\)](#)

Perea-Arango,Ismael Leon-Rivera

Pharmacognosy Journal,13(5):1161-1173

DOI: 10.5530/pj.2021.13.149


Published: Thu, 2-Sep-2021

[Read More \(/article/1646\)](#)

Research Article

The Potential Interaction of Ethionamide-Thyroid Hormone Receptor Induces Hypothyroidism (/article/1647)

Ronny Lesmana,Firyali Rahmani Shidqi,Hanna Goenawan,Iwan Setiawan,Marisca Evalina Gondokesumo,Farida Suhud,Nasrul Wathoni



Pharmacognosy Journal,13(5):1174-1179

DOI: 10.5530/pj.2021.13.150

Published: Thu, 2-Sep-2021

[Read More \(/article/1647\)](#)

Research Article

Study of the Making of Hydrolizate Protein Powder of Rebon Shrimp as a Food Nutrition Enhancement Ingredient (/article/1648)


, , ,Taufik Hidayat

Pharmacognosy Journal,13(5):1180-1185

DOI: 10.5530/pj.2021.13.151

Published: Thu, 2-Sep-2021


[Read More \(/article/1648\)](#)



Research Article

Pharmacognostic Specifications, RP-HPLC Analysis of Chlorogenic Acid Content and Antioxidant Activity of Morus alba Linn. Leaves in Thailand (/article/1649)

Phimkun Aiyarakanchanakun,Chanida Palanuvej,Nijsiri Ruangrungsi,Anuchit Phanumartwiwath



Pharmacognosy Journal,13(5):1186-1194

DOI: 10.5530/pj.2021.13.152


Published: Mon, 13-Sep-2021

[Read More \(/article/1649\)](#)

Research Article

Impact of Solvent Selection on Phytochemical Content, Recovery of Tannin and Antioxidant Activity of Quercus Infectoria Galls (/article/1650)

Nur Alisa Kamarudin,Norhazilah Muhamad,Nik Nur Hakima Salleh,Suat Cheng Tan



Pharmacognosy Journal,13(5):1195-1204

DOI: 10.5530/pj.2021.13.153

Published: Wed, 8-Sep-2021

[Read More \(/article/1650\)](#)

Research Article

Chemical Composition and Protective Effect of Rosmarinus officinalis on Alcohol-Induced Serum Hepatic Changes and Liver Injury in Male Rats (/article /1651)



Pharmacognosy Journal, 13(5):1205-1215

DOI: 10.5530/pj.2021.13.154


Published: Thu, 2-Sep-2021

[Read More \(/article/1651\)](#)

Research Article

Separation and Quantification of Sinensetin, Imperatorin and Total Tannin Content as Active Phytoconstituents of Methanol Extract of Imperata cylindrica Root from Kendari (/article/1652)

Diah Dhianawaty, Mas Rizky Angg Syamsunarno, Resti Gradia Dwiwina, Raden Anita Indriyanti,



[\(/article/1652\)](#)

Pharmacognosy Journal, 13(5):1216-1224

DOI: 10.5530/pj.2021.13.155


Published: Thu, 2-Sep-2021

[Read More \(/article/1652\)](#)

Research Article

Phytochemical Screening and Anti-Inflammatory Potential of the Organic Extracts from Cleoserrata serrata (Jacq.) Iltis. (/article/1653)

María del Carmen Juárez-Vázquez, Alejandro Zamilpa A, Rosalba León-Díaz, Mariano Martínez-Vázquez, Adolfo López-Torres, Julieta Luna-Herrera, Lilian Yépez-Mulia, Francisco Alarcón-Aguilar, María Adelina Jiménez-Arellanes



[\(/article/1653\)](#)

Pharmacognosy Journal, 13(5):1225-1241

DOI: 10.5530/pj.2021.13.156

Published: Thu, 2-Sep-2021

[Read More \(/article/1653\)](#)

Research Article

Microwave-Assisted Extraction and Identification of γ -Oryzanol from Rice Bran (*Oryza sativa* L. cv Ciliwung) (/article/1654)

,Netti Herawati, Meuthia Aulia Farh Gaffar, , Elly Wahyudin



[\(/article/1654\)](#)

Pharmacognosy Journal, 13(5):1242-1247

DOI: 10.5530/pj.2021.13.157

Published: Thu, 2-Sep-2021

[Read More \(/article/1654\)](#)

Research Article

Antimicrobial Efficacy, Cytotoxicity, Acute Oral Toxicity, and Phytochemical Investigation of the Aqueous and Methanolic Stem Bark Extracts of *Bridellia micrantha* (Hochst.) Baill (/article/1655)

Joseph M. Kathare, James M. Mbaria, Joseph M. Nguta, Gervason A. Moriasi, Alfred O. Mainga



[\(/article/1655\)](#)

Pharmacognosy Journal, 13(5):1248-1256

DOI: 10.5530/pj.2021.13.158

Published: Mon, 13-Sep-2021

[Read More \(/article/1655\)](#)

Research Article

Amelioration of Cisplatin-Induced Kidney Injury by *Pometia pinnata* (/article



/1656)


,RA Syahputra,Sukirman Lie,SE Nugraha,PC Situmorang

Pharmacognosy Journal,13(5):1257-1268

DOI: 10.5530/pj.2021.13.159

Published: Thu, 2-Sep-2021

[Read More \(/article/1656\)](#)



Research Article

In Vivo Antimammary Tumor Effects of Soybean Extract with Targeted Lunasin (ET-Lun) (/article/1657)


Numlil Khaira Rusdi,Erni Hernawati Purwaningsih,Andon Hestiantoro,Berna Elya,Kusmardi Kusmardi

Pharmacognosy Journal,13(5):1269-1276

DOI: 10.5530/pj.2021.13.160

Published: Thu, 2-Sep-2021

[Read More \(/article/1657\)](#)



Research Article

Determination of Urinary Methyl Hippuric Acid Using Shimadzu UV-Visible Spectrophotometer Among Petroleum Employees (/article/1658)

Vidya Gowdappa Doddawad,B.M. Gurupadayya,Shivananda S,Vidya CS,Azhar Mohammed,Bhuyan L

Pharmacognosy Journal,13(5):1277-1281

DOI: 10.5530/pj.2021.13.161

Published: Thu, 2-Sep-2021

[Read More \(/article/1658\)](#)



Research Article

Analysis of Three-Dimensional Protein Structure of CBAVD in Indonesia as a Basis for Immunotherapy to Ensure Maternal Health (/article/1659)


Maslichah Mafruchati,Jonathan Makuwira

Pharmacognosy Journal,13(5):1282-1286

DOI: 10.5530/pj.2021.13.162

Published: Thu, 2-Sep-2021

[Read More \(/article/1659\)](#)



Research Article

Antioxidant Capacity of Chuquiraga Spinosa Less. "Huamanpinta" and Prevention of Carrageenan-Induced Inflammation in Mice (/article/1660)


Hugo Jesús Justil-Guerrero,Jorge Luis Arroyo-Acevedo,Juan Pedro Rojas-Armas,Miriam Palomino Pacheco,Magaly Villena-Tejada,Wilmer Atilio Seg Vilchez

Pharmacognosy Journal,13(5):1287-1296

DOI: 10.5530/pj.2021.13.163

Published: Thu, 2-Sep-2021


[Read More \(/article/1660\)](#)



Research Article

Application of Ultrasound-Assisted Extraction on the Stem Bark of Rhinachantus Nasutus (L.) Kurz, Total Phenolic, and Its Potential as Antioxidant and Inhibitor of Alpha-Glucosidase Enzyme Activity (/article/1661)





Pharmacognosy Journal,13(5):1297-1303

DOI: 10.5530/pj.2021.13.164


Published: Thu, 2-Sep-2021

[Read More \(/article/1661\)](#)

Research Article

Synergistic Efficacy of Phytochemical, Antioxidant and Bactericidal Properties of the Aerial Essential Oil of *Laggera crispata* (/article/1662)

Ololade Zacchaeus S,Anuoluwa Iyadunni A,Adeyemi Adewale F,Uyaboerigha Daubotei I



Pharmacognosy Journal,13(5):1304-1311

DOI: 10.5530/pj.2021.13.165


Published: Thu, 2-Sep-2021

[Read More \(/article/1662\)](#)

Review article

Potential Neuroprotective Activity of Essential Oils in Memory and Learning Impairment (/article/1663)

Carmen R. Silva-Correa,Jorge L. Campos-Reyna,Víctor E.Villarr La Torre,Abhel A. Calderón-Peña,William Antonio Sagástegui-Guarniz,Luz M. Guerrero-Espino,Anabel D. González-Siccha,Cinthy L. Aspajo-Villalaz,María V. González-Blas,José L. Cruzado-Razco,Julio Hilario-Vargas



Pharmacognosy Journal,13(5):1312-1322

DOI: 10.5530/pj.2021.13.166

Published: Thu, 2-Sep-2021

[Read More \(/article/1663\)](#)

Submit your Next Article

- Online submission
- Highly indexed and abstracted
- 10 years of successful publishing
- Wider visibility though open access
- Higher impact with wider visibility
- Prompt review

Submit your next article to Phcog J

and be a part of many successful authors.

Create free account (<http://phcogj.info/>) / Login (<https://www.phcogj.com/submissions/index.php/phcogj/index>)

About

Pharmacognosy Journal (Phcog J.) covers different topics in natural product drug discovery, and also publishes manuscripts that describe pharmacognostic investigations, evaluation reports, methods, techniques and applications of all forms of medicinal plant research

Distinctions: The most widely read, cited, and known Pharmacognosy journal and website is well browsed with all the articles published. More than 50,000 readers in nearly every country in the world each month

ISSN : 0975-3575 ; Frequency : Rapid at a time publication (6 issues/year)

Indexed and Abstracted in : SCOPUS, Scimago Journal Ranking, Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI E-Text, Index Copernicus, Ulrich's International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.



Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.

Open Access Journal: Pharmacognosy Journal is an open access journal, which allows authors to fund their article to be open access from publication.

Submit your Next Article

- Online submission
- Highly indexed and abstracted
- 10 years of successful publishing
- Wider visibility though open access
- Higher impact with wider visibility
- Prompt review

Submit your next article to Phcog J

and be a part of many successful authors.

Create free account (<http://phcogj.info>) / Login (<https://www.phcogj.com/submissions/index.php/phcogj/index>)

Copyright © 2020 Pharmacogn J. All rights reserved.

Pharmacognosy Journal and its contents are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 4.0 License. Permissions beyond the scope of this license may be available with editor@phcogj.com (<mailto:editor@phcogj.com>)

[Home \(/\)](#)

[Advertise with us \(/\)](#)

[Privacy Statement \(/\)](#)



Pharmacognosy Journal

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
India  Universities and research institutions in India  Media Ranking in India	Pharmacology, Toxicology and Pharmaceutics Drug Discovery Pharmacology	EManuscript Technologies	30
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	09753575	2009-2022	Homepage How to publish in this journal editor@phcogj.com

SCOPE

Pharmacognosy Journal (Phcog J.) covers different topics in natural product drug discovery, and also publishes manuscripts that describe pharmacognostic investigations, evaluation reports, methods, techniques and applications of all forms of medicinal plant research


 Join the conversation about this journal

 Quartiles

FIND SIMILAR JOURNALS

options 

1 Oriental Pharmacy and Experimental Medicine USA 82% similarity	2 Pharmacognosy Research IND 81% similarity	3 Indian Journal of Natural Products and Resources IND 77% similarity	4 Journal of Herbs, Spices and Medicinal Plants USA 76% similarity	5 Pharmacognosy Magazine IND 76% similarity
--	---	---	--	---



Pharmacognosy Journal

← Show this widget in your own website

Just copy the code below and paste within your html code:

Q3 Pharmacology
best quartile

SJR 2022
0.23

powered by scimagojr.com

```
<a href="https://www.scimagojr.com" data-bbox="198 433 296 443">
```

SCImago Graphica

Explore, visually communicate and make sense of data with our new data visualization tool.

Metrics based on Scopus® data as of April 2023


C **Candle** 2 months ago
Expensive publication fee!
reply

 **Melanie Ortiz** 2 months ago
Dear Candle, thanks for your participation! Best Regards, SCImago Team

SCImago Team

 **Ravens Genesis** 3 months ago
Be careful with this journal, they publish articles that are inappropriate and very different from the scope of the journal. They even publish several articles at the same time in one issue by the same author!
reply

E **edi utomo** 1 year ago
I want to get information about drug poison crimes, is there a journal about this?
reply

 **Melanie Ortiz** 1 year ago
Dear Edi,
Thank you for contacting us.
We suggest you use the Journal Rankings' Search Tool shown on our website, as the journals can be filtered by Subject Area/ Category.

SCImago Team

K **Kori Yati** 2 years ago

I want to submit an article, can I send a link?

reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Kori, thank you very much for your comment, we suggest you look for the author's instructions/submission guidelines in the journal's website. Best Regards, SCImago Team

N **Najib** 3 years ago

Is this journal still indexed by scopus or have been discontinued?

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Najib,
Thank you very much for your comment.
All the metadata have been provided by Scopus /Elsevier in their last update sent to SCImago, including the Coverage's period data. The SJR for 2020 has been released on 17 May 2021. We suggest you consult the Scopus database directly to see the current index status as SJR is a static image of Scopus, which is changing every day.
Best Regards, SCImago Team

P **Prena Sharma** 3 years ago

Dear sir/Mam,
I just want to know that is these journals are the SCI E and Whats the publication charges of research article.
kindly suggest
Regards

reply

A **Ali** 3 years ago

What about the pharmacognosy journal? Is it indexed journal



Melanie Ortiz 3 years ago

SCImago Team

Dear Prena,
Thank you for contacting us.
SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request referring to the index status. We suggest you consult Scopus database (see the current status of the journal) or the mentioned database. For further information about this journal, please visit the journal's website or contact directly with the editorial staff.
Best Regards, SCImago Team

T **Tushar** 4 years ago

Dear sir/Mam,
I just want to know that is these journals in the UGC care list because I didn't get the updated list of UGC.
kindly do needful

reply



Melanie Ortiz 4 years ago

SCImago Team

Dear Tushar,
Thank you for contacting us. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request referring

the index status. We suggest you to consult Scopus database (see the current status of the journal) or other databases (like WoS) for further information. You can also check that information in the journal's website or contact directly with the editorial staff. Best Regards, SCImago Team

A **aditi** 5 years ago

Respected Sir,

I wish to know if while writing manuscript got Pharmacognosy journal, Can the results and discussion be combined?

reply



Elena Corera 5 years ago

SCImago Team

Dear Aditi,

thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you check author's instructions in journal website. You can find that information in SJR website <https://www.scimagojr.com>

Best Regards,
SCImago Team

Leave a comment

Name

Email

(will not be published)



Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Journal Rank 1.1. 2022

[Cookie settings](#)

[Cookie policy](#)



Source details

Pharmacognosy Journal

Scopus coverage years: from 2009 to 2023

Publisher: EManuscript Technologies

ISSN: 0975-3575

Subject area: [Pharmacology, Toxicology and Pharmaceutics: Pharmacology](#)

[Pharmacology, Toxicology and Pharmaceutics: Drug Discovery](#)

Source type: Journal

CiteScore 2022

1.9



SJR 2022

0.229



SNIP 2022

0.484



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

CiteScore 2022

$$1.9 = \frac{1,691 \text{ Citations 2019 - 2022}}{878 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$2.2 = \frac{1,855 \text{ Citations to date}}{851 \text{ Documents to date}}$$

Last updated on 05 January, 2024 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#219/301	27th
└ Pharmacology		
Pharmacology, Toxicology and Pharmaceutics	#121/156	22nd
└ Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

All content on this site: Copyright © 2024 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.

